PMID- 35137332
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220718
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 40
IP  - 3
DP  - 2022 Jun
TI  - Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment 
      of central nervous system lymphoma: a retrospective study.
PG  - 650-659
LID - 10.1007/s10637-022-01219-5 [doi]
AB  - BACKGROUND: Central nervous system lymphoma (CNSL) is an aggressive lymphoma. 
      Orelabrutinib, an oral Bruton tyrosine kinase inhibitor, is a new treatment 
      strategy for CNSL. This study aims to evaluate the efficacy and safety of 
      orelabrutinib-based regimens in the treatment of patients with CNSL. METHODS: 
      Twenty-three patients with CNSL were included in this retrospective study. All 
      patients received the orelabrutinib-based regimen. Efficacy was evaluated based 
      on investigators' assessment of overall response rate (ORR), complete 
      response/unconfirmed complete response (CR/CRu), partial response (PR), stable 
      disease (SD), progressive disease (PD), duration of response (DOR), 
      progression-free survival (PFS) and overall survival (OS). The safety of 
      orelabrutinib-based regimens has also been evaluated. RESULTS: A total of 17.39% 
      of patients received orelabrutinib-based regimens for consolidation therapy, and 
      82.61% of patients for induction therapy (4 newly diagnosed CNSL, 15 
      relapsed/refractory CNSL). In the newly diagnosed CNSL group, the ORR was 100% (1 
      CR, 1 CRu, 2 PR). The 6-month DOR rate, 6-month PFS rate, and 6-month OS rate 
      were 100%, 100%, and 100%, respectively. Of the 15 relapsed/refractory CNSL 
      patients, five therapy regimens were applied (orelabrutinib, n = 3; 
      orelabrutinib/immunotherapy, n = 3; orelabrutinib/chemotherapy, n = 2; 
      orelabrutinib/immunochemotherapy, n = 6; orelabrutinib/radiotherapy, n = 1). The 
      ORR was 60.00% (4 CR, 5 PR). The 6-month DOR rate, 6-month PFS rate, and 6-month 
      OS rate were 92.30%, 67.70%, and 70.00%, respectively. Twenty-one patients 
      reported adverse events (AEs), and 6 patients experienced grade >/= 3 AEs. 
      CONCLUSION: Orelabrutinib-based regimens were efficacious and well-tolerated in 
      patients with CNSL. These combined therapies offer a new potential therapeutic 
      strategy for patients with CNSL.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Wu, Jing-Jing
AU  - Wu JJ
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Wang, Wen-Hua
AU  - Wang WH
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Dong, Meng
AU  - Dong M
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Ma, Shan-Shan
AU  - Ma SS
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Zhang, Xu-Dong
AU  - Zhang XD
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Zhu, Li-Nan
AU  - Zhu LN
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Niu, Song-Tao
AU  - Niu ST
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Ding, Meng-Jie
AU  - Ding MJ
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Zhang, Jie-Ming
AU  - Zhang JM
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Li, Xin
AU  - Li X
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Li, Ling
AU  - Li L
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Sun, Zhen-Chang
AU  - Sun ZC
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Wang, Xin-Hua
AU  - Wang XH
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Fu, Xiao-Rui
AU  - Fu XR
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Li, Zhao-Ming
AU  - Li ZM
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Chang, Yu
AU  - Chang Y
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Nan, Fei-Fei
AU  - Nan FF
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Yan, Jia-Qin
AU  - Yan JQ
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Yu, Hui
AU  - Yu H
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Wu, Xiao-Long
AU  - Wu XL
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Zhou, Zhi-Yuan
AU  - Zhou ZY
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China.
FAU - Zhang, Ming-Zhi
AU  - Zhang MZ
AUID- ORCID: 0000-0003-3581-551X
AD  - Department of Oncology, the First Affiliated Hospital of Zhengzhou University, 
      No. 1, Jianshe East Road, Zhengzhou, Henan, 450052, China. 
      mingzhi_zhang1@163.com.
LA  - eng
PT  - Journal Article
DEP - 20220209
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Central Nervous System
MH  - *Central Nervous System Neoplasms/drug therapy
MH  - Humans
MH  - *Lymphoma, Non-Hodgkin/drug therapy
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Bruton tyrosine kinase
OT  - Central nervous system lymphoma
OT  - Orelabrutinib
OT  - Prognosis
EDAT- 2022/02/10 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/02/09 06:02
PHST- 2021/11/19 00:00 [received]
PHST- 2022/01/21 00:00 [accepted]
PHST- 2022/02/10 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/02/09 06:02 [entrez]
AID - 10.1007/s10637-022-01219-5 [pii]
AID - 10.1007/s10637-022-01219-5 [doi]
PST - ppublish
SO  - Invest New Drugs. 2022 Jun;40(3):650-659. doi: 10.1007/s10637-022-01219-5. Epub 
      2022 Feb 9.